Biocept (BIOCQ) 10-Q 23 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 16, 2022
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	BIOC
Entity Registrant Name	Biocept, Inc.
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		16,922,868
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36284
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0943522
Entity Address, Address Line One	9955 Mesa Rim Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	320-8200
Title of 12(b) Security	Common Stock, par value $.0001 per share
Entity Shell Company	false
Entity Current Reporting Status	Yes
Security Exchange Name	NASDAQ

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 27,566	$ 28,864
Accounts receivable, net	16,351	13,786
Inventories, net	3,221	2,651
Prepaid expenses and other current assets	446	391
Total current assets	47,584	45,692
Fixed assets, net	2,380	2,401
Lease right-of-use assets - operating	8,892	9,026
Lease right-of-use assets - finance	2,617	2,842
Other non-current assets	471	456
Total assets	61,944	60,417
Current liabilities:
Accounts payable	8,076	7,246
Accrued liabilities	4,550	3,018
Current portion of lease liabilities - operating	449	426
Current portion of lease liabilities - finance	1,021	1,083
Total current liabilities	14,096	11,773
Non-current portion of lease liabilities - operating	9,598	9,736
Non-current portion of lease liabilities - finance	1,221	1,428
Total liabilities	24,915	22,937
Commitments and contingencies (see Note 10)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 2,106 shares and 2,090 shares issued and outstanding at December 31, 2021 and March 31, 2022, respectively.
Common stock, $0.0001 par value, 150,000,000 shares authorized; 16,849,805 shares and 16,850,161 shares issued and outstanding at December 31, 2021 and March 31, 2022, respectively.	2	2
Additional paid-in capital	306,146	303,829
Accumulated deficit	(269,119)	(266,351)
Total shareholders’ equity	37,029	37,480
Total liabilities and shareholders’ equity	$ 61,944	$ 60,417

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,090	2,106
Preferred stock, shares outstanding	2,090	2,106
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	16,850,161	16,849,805
Common stock, shares outstanding	16,850,161	16,849,805

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net revenues	$ 19,945	$ 17,756
Costs and expenses:
Cost of revenues	10,335	9,006
Research and development expenses	1,851	1,043
General and administrative expenses	6,806	3,120
Sales and marketing expenses	3,660	1,923
Total costs and expenses	22,652	15,092
(Loss)/Income from operations	(2,707)	2,664
Other income/(expense):
Interest expense, net	(61)	(65)
Total other income/(expense):	(61)	(65)
(Loss)/income before income taxes	(2,768)	2,599
Net (loss)/income and comprehensive (loss)income	(2,768)	2,599
Net (loss)/income attributable to common shareholders	$ (2,768)	$ 2,599
Weighted-average shares outstanding used in computing net (loss)income per share attributable to common shareholders:
Basic	16,849,964	13,400,007
Diluted	16,849,964	13,667,716
Net (loss)/income per common share:
Basic	$ (0.16)	$ 0.19
Diluted	$ (0.16)	$ 0.19

Condensed Statements of Shareho

Condensed Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Series A Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ 23,692	$ 1		$ 287,218	$ (263,527)
Beginning balance, shares at Dec. 31, 2020		13,397,041	2,111
Stock-based compensation expense	460			460
Shares issued upon exercise of common stock warrants	19			19
Shares issued upon exercise of common stock warrants, shares		5,304
Shares issued upon conversion of preferred stock, shares		23
Shares issued upon exercise of options	1			1
Shares issued upon exercise of options, shares		194
Net income (loss)	2,599				2,599
Ending balance at Mar. 31, 2021	26,771	$ 1		287,698	(260,928)
Ending balance, shares at Mar. 31, 2021		13,402,562	2,111
Beginning balance at Dec. 31, 2020	23,692	$ 1		287,218	(263,527)
Beginning balance, shares at Dec. 31, 2020		13,397,041	2,111
Net income (loss)	(2,800)
Ending balance at Dec. 31, 2021	37,480	$ 2		303,829	(266,351)
Ending balance, shares at Dec. 31, 2021		16,849,805	2,106
Stock-based compensation expense	2,317			2,317
Shares issued upon conversion of preferred stock, shares		356	(16)
Net income (loss)	(2,768)				(2,768)
Ending balance at Mar. 31, 2022	$ 37,029	$ 2		$ 306,146	$ (269,119)
Ending balance, shares at Mar. 31, 2022		16,850,161	2,090

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash Flows from Operating Activities
Net Income(loss )	$ (2,768)	$ 2,599
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	405	366
Amortization of right-of-use assets	414	362
Inventory reserve	78	(9)
Stock-based compensation	2,317	460
Loss (gain) on disposal of fixed assets		4
Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net	(2,564)	(2,998)
Inventory	(648)	(1,320)
Prepaid expenses and other current assets	(49)	1,454
Other non-current assets	(16)	(13)
Accounts payable	375	(333)
Accrued liabilities	1,524	272
Net cash (used in)/provided by operating activities	(932)	844	$ 800
Cash Flows from Investing Activities:
Purchases of fixed assets	(98)	(712)
Net cash used in investing activities	(98)	(712)
Cash Flows from Financing Activities:
Proceeds from exercise of common stock warrants		18
Proceeds from exercise of overallotment warrants		1
Payments on finance leases	(268)	(321)
Net cash used in financing activities	(268)	(302)
Net decrease in Cash	(1,298)	(170)
Cash at Beginning of Period	28,864	14,368	14,368
Cash at End of Period	27,566	14,198	$ 28,864
Supplemental Disclosures of Cash Flow Information:
Interest	$ 61	$ 65

Condensed Statements of Cash _2

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement Of Cash Flows [Abstract]
Fixed assets purchased under finance lease obligations	$ 0	$ 894,000
Unpaid fixed assets	$ 60,000	$ 319,000

The Company, Business Activitie

The Company, Business Activities and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
The Company, Business Activities and Basis of Presentation	1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF The identification of tumor cells and cell-free tumor DNA in CSF has become the Company’s principal development focus following its early commercial expansion into CSF in 2020. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly owned subsidiary of the Company since July 23, 2013. The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the emergence and impact of variants, vaccinations, government funding for COVID-19 testing, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The Company experienced increased revenue levels in 2021 and 2022 related to its COVID-19 testing business. Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2021, filed with the SEC with our Annual Report on Form 10-K on April 5, 2022 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. A novel strain of coronavirus, or COVID COVID COVID Significant Accounting Policies During the three months ended March 31, 2022, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians and other healthcare providers, the Company provides services that benefit the patient. Patients do not typically enter into direct agreements with the Company; however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with the Centers for Medicare & Medicaid Services, or CMS, and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, such as pharma or biotech organizations, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks, and for our RT-PCR COVID-19 testing, typically 48 hours or less. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services is established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Further, although the Company believes that its estimate for contractual allowances and other reserves is appropriate, it is possible that the Company will experience an impact on cash collections as a result of the impact of the COVID-19 pandemic. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three months ended March 31, 2021 and 2022, disaggregated by source and nature, are as follows: For the Three Months Ended March 31, 2021 2022 Net revenues from non-contracted payers $ 6,314 $ 7,262 Net revenues from contracted payers* 11,341 12,645 Net commercial revenues 17,655 19,907 Development services revenues 39 38 Kits and Specimen Collection Tubes (SCTs) 62 — Total net revenues $ 17,756 $ 19,945 *Includes Medicare, Medicare Advantage and CARES Act as reimbursement amounts are fixed. Revenues for the three months ended March 31, 2021 and 2022 included $17.7 million and $19.9 million, respectively, in commercial test revenues, including $16.8 million and $18.6 million of revenues attributable to RT-PCR COVID-19 testing. During the three months ended March 31, 2022, no additional account receivable reserves were required, and the Company had approximately $0.6 million in account receivable recoveries for aged receivable balances reserved in prior periods. For the Three Months Ended March 31, 2021 2022 Net commercial revenues $ 17,655 $ 19,907 Development services revenues 39 38 Kits and Blood Collection Tubes (BCT) 62 — Total net revenues $ 17,756 $ 19,945 At March 31, 2021 and March 31, 2022, unbilled account receivables totaled approximately $4.3 million and $2.7 million, respectively. Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2021, and 2022 were as follows: For the Three Months Ended March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 35% 43% Blue Cross Blue Shield 30% 16% Kaiser Permanente 3% 14% The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2021 and March 31, 2022 were as follows: December 31, March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 31% 36% Blue Cross Blue Shield 19% 16% Recent Accounting Pronouncements None.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Liquidity	2. Liquidity As of March 31, 2022, cash totaled $27.6 million and the Company had an accumulated deficit of $269.1 million. For the year ended December 31, 2021 and the three months ended March 31, 2022, the Company incurred a net loss of $2.8 million and The Company has historically funded its operations primarily through sales of its equity securities. For the year ended December 31, 2021, revenue from the Company’s COVID-19 testing business provided an increase level of cash flow. During the quarter ended March 31, 2022, net revenues were approximately $19.9 million compared with approximately $17.8 million for the same period in the prior year, and the Company had a net loss of $2.8 million and net cash used in operations of $0.9 million. The Company believes that based on its current and planned cash usage, along with current and projected COVID-19 testing revenues, its cash balances will support operations through at least 12 months following the issuance of the accompanying unaudited condensed financial statements. As such, the Company determined that it is not probable based on projected cash flows that substantial doubt about the Company’s ability to continue as a going concern exists for the one-year period following the date that the financial statements for the three months ended March 31, 2022 were issued. The Company’s determination was based on estimates regarding expected COVID-19 testing volumes for which the Company is currently seeing a reduced demand and expect this trend to continue absent a negative and sustained turn in the course of the pandemic. The Company used all information currently available to make this determination. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company will need to generate significant growth in net revenues to achieve and sustain income from operations. In order to meet its long-term operating requirements beyond the next twelve months, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. The Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all.

Sales of Equity Securities

Sales of Equity Securities	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities As part of a warrant repricing and exchange transaction, in January 2020, the Company issued an aggregate of 692,725 new warrants in exchange for the exercise of certain warrants issued by the Company in February 2019 and March 2019 for an aggregate of 692,725 shares of common stock and received net proceeds of approximately $2.3 million. As a result of the warrant repricing, the exercise price of warrants to purchase an aggregate of 89,657 shares of common stock issued by the Company in January 2018 was adjusted from $4.05 to $3.495 per share. In January 2020, the Company issued 192,750 shares of common stock pursuant to the partial exercise of the underwriters’ overallotment option from the Company’s December 2019 public offering. The net proceeds to the Company from the overallotment closing was approximately $700,000. The warrants issued in connection with the warrant repricing and exchange transaction were considered inducement warrants and are classified in equity. In addition, the modification expense associated with the change in fair value due to the repricing of February and March 2019 warrants is recorded as inducement expense, which was approximately $191,000. The fair value of the warrants issued was approximately $1.9 million. The fair value of the inducement warrants and warrant modification of $2.1 million was expensed as warrant inducement expense during the year ended December 31, 2021. On May 12, 2021, the Company entered into a Controlled Equity Offering SM The obligations of the Sales Agent under the Sales Agreement to sell the Company’s common stock are subject to a number of conditions that the Company must meet. The offering of common stock pursuant to the Sales Agreement will terminate upon the earlier of (1) the sale of all common stock subject to the Sales Agreement and (2) termination of the Sales Agreement as permitted therein. The Sales Agreement may be terminated by the Company at any time upon ten days’ notice. The Sales Agent may terminate the Sales Agreement at any time upon ten days ’ prior notice. The Sales Agent is entitled to compensation from the Company at a fixed commission rate equal to 3.0 % of the gross sales price per share of any common stock sold under the Sales Agreement . During 2021, we received net proceeds of $14.1 million from the sale of our common stock and issued 3,428,680 shares of our common stock at a weighted average purchase price of $4.31 pursuant to the Sales Agreement. As of March 31, 2022, $10.2 million of our common stock remained available for sale under the sales agreement.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $0.9 million for the three months ended March 31, 2021 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates. There were no fixed asset purchases recorded as right-of-use assets for the three months ended March 31, 2022 Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on the present value of future lease payments based on contractual payment amounts and estimated market rates in effect. Other Fair Value Measurements As of the closing of the Company’s January 2020 warrant repricing and exchange transaction, the estimated grant date fair value of approximately $2.80 per share associated with the warrants to purchase up to 692,725 shares of common stock issued in the transaction, or a total of approximately $1.9 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $3.495 per share, became exercisable beginning 6 months from issuance and expire 5.5 years from the date of issuance. Beginning stock price $ 3.00 Exercise price $ 3.495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 % In addition to the inducement warrants issued in the Company’s January 2020 warrant repricing and exchange transaction, the Company adjusted the exercise prices of the February 2019 and March 2019 warrants from $12.00 and $12.50, respectively, to $3.495 to induce exercise of these warrants. This price modification triggered the requirement for modification accounting of these warrants. Based on the applicable guidance, the modification required the Company to value the modified February 2019 and March 2019 warrants immediately prior to the modification of the exercise price and immediately following the modification and record the difference between the resulting two values as warrant inducement expense. The estimated fair value prior to modification of the February 2019 and March 2019 warrants was approximately $2.70 per share, whereas the estimated fair value of the February 2019 warrants increased to $2.90 due to the adjustment of the exercise price, and the estimated fair value of the March 2019 warrants increased to $3.00 per share. There were 216,725 February 2019 warrants and 476,000 March 2019 warrants eligible for this price modification and the resulting modification expense recorded as warrant inducement expenses were $60,000 and $130,000, respectively.

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2022
Balance Sheet Component [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, March 31, 2021 2022 (unaudited) Inventories Raw materials $ 2,303 $ 2,735 Subassemblies 294 414 Finished goods 54 72 $ 2,651 $ 3,221 Fixed Assets Machinery and equipment $ 3,063 $ 3,079 Furniture and office equipment 161 161 Computer equipment and software 2,931 2,931 Leasehold improvements 634 634 Construction in process 245 387 $ 7,034 $ 7,192 Less: accumulated depreciation and amortization (4,633 ) (4,812 ) Total fixed assets, net $ 2,401 $ 2,380 Accrued Liabilities Accrued payroll 725 992 Accrued vacation 961 818 Accrued bonuses 178 493 Accrued sales commissions 600 1,813 Accrued other 554 434 Total accrued liabilities $ 3,018 $ 4,550

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	6. Leases Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Fixed Assets on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Finance Leases The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight-line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 5 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $6.0 at December 31, 2021 and March 31, 2022, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $3.2 million and $3.4 million at December 31, 2021 and March 31, 2022, respectively. Total depreciation expense related to equipment under finance leases during the three months ended March 31, 2021, and 2022 was approximately $172,000 and $225,000, respectively. During the three months ended March 31, 2021, the Company entered into finance leases for a total capitalized amount of $894,000 for four pieces of equipment. Under the terms of the financing agreements, which were accounted for as finance lease transactions, the principal balance plus interest for the equipment are to be paid in installments ranging from 36 to 60 monthly installments of $21,330 totaling approximately $1.1 million through March 2026. During the three months ended March 31, 2022, the Company did not enter into any additional financed leases obligations Operating Lease The Company leases its primary laboratory and office facilities in San Diego, California. In accordance with the ASC 842 guidance, the facility lease is classified as an operating lease. From its inception until December 2020, the Company’s primary facilities were located at 5810 Nancy Ridge Road in San Diego, California (Nancy Ridge Facility) and subject to a lease agreement dated March 31, 2004. On June 5, 2020, the Company entered into a fifth amendment (the “Amendment”) to its lease agreement relating to the Nancy Ridge Facility. Pursuant to the Amendment, the expiration date of the lease was extended from July 31, 2020 to November 30, 2020. The monthly base rent during the extended term was the then-current monthly rate paid by the Company. The Company agreed to pay additional rent and all other charges as set forth in the lease through the expiration date. Pursuant to the extension of the expiration date of the lease, the Company recorded an additional lease right-of-use asset and lease liability of $482,000. In order to allow the Company adequate time to move its operations to its new facility, the Company entered into an additional extension related to the facility extending the lease until December 11, 2020 at the prorated amount of the then-current rent. On June 1, 2020, the Company entered into a lease for a 39,000 square foot headquarters, manufacturing and laboratory facility at 9955 Mesa Rim Road in San Diego, California. The lease commenced on December 1, 2020 and is for a term of 127 months from the commencement date. The lease includes a rent abatement period of seven months, from January 2021 through July of 2021, during which period the Company is exempted from paying the amount of base rent of $111,000. In addition, the lease stipulates an additional two months of lease abatement period in the event that the property is sold within the first six months of the initial lease period. In March 2021, the Company was notified that the original landlord has sold the building, hence the Company is eligible for an additional two months of rent abatement period. In addition, the landlord agreed to pay for certain preapproved leasehold improvement costs through a one-time leasehold improvement allowance of approximately $1.6 million. The amount of additional leasehold improvement allowance of approximately $1.6 million is to be paid back to the landlord during the term of the lease by the Company, amortized at an agreed upon annual rate of 7% as an additional rent payment of approximately $18,000 per month. The average monthly cash payment including payment for the additional leasehold improvement allowance for the lease is approximately $140,000 per month with initial monthly lease payments of $128,000 per month. The Company recorded a lease right-of-use asset and lease liability of $9.8 million and $9.8 million, respectively, as of December 31, 2020, based on the present value of payments and an incremental borrowing rate of 12%. As the Company’s lease did not provide an implicit rate, the Company estimated the incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings. The Company recorded $1.6 million in other current assets related to reimbursable leasehold improvement costs incurred as of December 31, 2020. The landlord reimbursed the Company $1.8 million during the year ended December 31, 2021. In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments. The following schedule sets forth the components of right-of-use lease assets as of December 31, 2021 and March 31, 2022 as follows: December 31, March 31, 2021 2022 Lease right-of-use assets: Operating $ 9,026 $ 8,892 Finance 2,842 2,617 Total $ 11,868 $ 11,509 The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2021 and March 31, 2022: December 31, March 31, 2021 2022 Current portion of lease liability: Operating $ 426 $ 449 Finance 1,083 1,021 Total $ 1,509 $ 1,470 The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2021 and March 31, 2022: December 31, March 31, 2021 2022 Long-term portion of lease liability: Operating $ 9,736 $ 9,598 Finance 1,428 1,221 Total $ 11,164 $ 10,819 The following schedule represents the components of lease expense for the three months ended March 31, 2021 and 2022: For the Three Months Ended March 31, 2021 2022 Lease cost Finance lease cost Amortization of right-of-use assets $ 172 $ 225 Interest on lease liabilities 65 61 Operating lease cost 415 415 Total $ 652 $ 701 The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of March 31, 2022: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2022 (Remaining 9 months) $ 819 $ 92 $ 1,191 2023 $ 963 $ 106 $ 1,629 2024 534 29 1,672 2025 185 3 1,715 2026 15 - 1,762 Thereafter - - 8,518 Total payments 2,516 230 16,487 Less amount representing interest (274 ) — (6,440 ) Present value of payments $ 2,242 $ 230 $ 10,047 The following schedule sets forth supplemental cash flow information related to operating and finance leases as of March 31, 2021 and March 31, 2022: For the Three Months Ended March 31, 2021 2022 Other information Operating cash flows from finance leases $ 65 $ 61 Operating cash flows from operating leases $ 53 $ 396 Financing cash flows from finance leases $ 321 $ 268 The aggregate weighted average remaining lease term was 2.5 years on finance leases and 9.25 years on operating leases as of March 31, 2022. The aggregate weighted average discount rate was 19.0% on finance leases and 12.0% on operating leases as of March 31, 2022. During the three months ended March 31, 2022, there were no additional exchanges of right of use assets for financed lease liabilities.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation Equity Incentive Plans The Company has two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. At the Company’s annual meeting of stockholders held on July 16, 2021, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 1,300,000 shares. As of March 31, 2022, 2,263,088 shares of the Company’s common stock were authorized exclusively for the issuance of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering employment with the Company, as defined under applicable Nasdaq Listing Rules. As of March 31, 2022, under all plans, a total of 4,599,497 shares were authorized for issuance consisting of 2,336,409 non-inducement stock options and 2,263,088 inducement stock options. As of March 31, 2022, 1,858,427 non-inducement shares and 1,599,918 inducement shares had been issued and 667,663 non-inducement shares and 513,032 inducement shares were available for grant. Outstanding awards as of March 31, 2022, consisted of 1,603,596 non-inducement shares and 1,599,918 inducement shares. Stock Options A summary of stock option activity for the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term in Years Outstanding at December 31, 2021 2,413,194 $ 7.04 9.06 Granted 1,155,570 $ 2.35 Cancelled/forfeited/expired (365,250 ) $ 6.44 Outstanding at March 31, 2022 3,203,514 $ 5.50 7.80 Vested and unvested expected to vest, March 31, 2022 3,162,485 $ 5.52 7.78 The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2021 and March 31, 2022 were each $610 and $0, respectively. The assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2022 were as follows: 2022 Stock and exercise prices $2.32 - $2.39 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.76% - 2.41% Expected life (in years) 5.55 - 6.03 Expected volatility 161% - 163% Restricted Stock The fair value of restricted stock units, or RSUs, awarded under either plan is determined by the closing price of the Company’s common stock on the date of grant. For non-performance RSUs, such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line method. The amount and timing of compensation expense recognized for RSUs is based on management’s estimate of the most likely outcome and when the achievement of the performance objectives is probable. There were no RSUs granted for the quarter ended March 31, 2022. At March 31, 2022, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were each approximately $84. Of the 36 RSUs outstanding, all were fully vested as of March 31, 2022. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the Three Months Ended March 31, 2021 2022 Stock Options Cost of revenues $ 94 $ 208 Research and development expenses 44 166 General and administrative expenses 260 1,802 Sales and marketing expenses 62 141 Total expenses related to stock options 460 2,317 As of March 31, 2022, total unrecognized share-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was $6.5 million and is expected to be recognized over a weighted-average period of approximately 2.97 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Common Stock Warrants Outstanding	8. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the three months ended March 31, 2022 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2021 857,261 $ 31.73 2.2 Issued — $ — — Exercised — $ — — Expired — $ — — Outstanding at March 31, 2022 857,261 $ 31.73 2.0 All warrants outstanding at December 31, 2021 and March 31, 2022 are exercisable. Warrants issued in the February 2019 financing transaction have an expiration date of February 12, 2024, warrants issued in the March 2019 transaction have an expiration date of September 19, 2024, warrants issued in the May 2019 inducement offering have an expiration date of December 2, 2024 , warrants issued in December 2019 have an expiration date of December 11, 2024 , and warrants issued in the January 2020 inducement offering have an expiration date of July 10, 2025 . The intrinsic value of equity-classified common stock warrants outstanding at December 31, 2021 and March 31, 2022 was $16,000 and $0, respectively.

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Common Share	9. Net Loss per Common Share Basic and diluted net income (loss) per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three months ended March 31, 2022, the outstanding RSUs, warrants and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. For the three months ended March 31, 2021, there is net income attributable to common shareholders and, as a result, 256,461 warrants and 102,708 options in the money were included in the calculation of dilutive weighted average shares. As these shares were in the money at March 31, 2021, an additional 267,709 shares were included in the calculation of diluted net income per share. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the Three Months Ended March 31, 2021 2022 Common warrants outstanding 991,863 857,261 RSUs outstanding 36 36 Convertible preferred stock outstanding (number of common stock equivalents) 46,651 46,136 Common options outstanding 1,213,284 3,203,514 Total anti-dilutive common share equivalents 2,251,834 4,106,947

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings except as provided in the paragraph below, and except for those proceedings that are not expected to have a material adverse effect on the Company’s financial condition, results of operations or liquidity. The Company is currently in mediation with a former employee and certain current employees regarding disputed claims for certain sales commissions. Although the Company is not in agreement with their interpretations or claims, the Company has entered into settlement negotiations related to the disputed commissions. Based on the mediation, there is a probable loss between $1.5 million and $1.8 million and therefore the Company accrued approximately $1.6 million in its commission accrual for the probable loss to be incurred by the Company in connection with the resolution of this matter.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions A former member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling approximately $36,000 and $49,000 during the years ended December 31, 2020 and 2021, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. On December 11, 2019, the Company entered into a First Amendment to Assignment and Exclusive Cross-License Agreement with Aegea pursuant to which the Company obtained a royalty bearing license for a certain patent. The Company agreed to pay Aegea, effective January 1, 2019, a royalty of 10% on the Company’s sale of research use only, or RUO and import research use only reagents and kits in the field of oncology, where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing. As of December 31, 2021 and March 31, 2022, no royalties have been accrued by the Company for royalty expenses related to this arrangement.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events None.

The Company, Business Activit_2

The Company, Business Activities and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
The Company and Business Activities	The Company and Business Activities The Company was founded in California in May 1997 and is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF The identification of tumor cells and cell-free tumor DNA in CSF has become the Company’s principal development focus following its early commercial expansion into CSF in 2020. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly owned subsidiary of the Company since July 23, 2013. The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, the emergence and impact of variants, vaccinations, government funding for COVID-19 testing, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The Company experienced increased revenue levels in 2021 and 2022 related to its COVID-19 testing business.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2021, filed with the SEC with our Annual Report on Form 10-K on April 5, 2022 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. A novel strain of coronavirus, or COVID COVID COVID
Significant Accounting Policies	Significant Accounting Policies During the three months ended March 31, 2022, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians and other healthcare providers, the Company provides services that benefit the patient. Patients do not typically enter into direct agreements with the Company; however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with the Centers for Medicare & Medicaid Services, or CMS, and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, such as pharma or biotech organizations, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks, and for our RT-PCR COVID-19 testing, typically 48 hours or less. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services is established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Further, although the Company believes that its estimate for contractual allowances and other reserves is appropriate, it is possible that the Company will experience an impact on cash collections as a result of the impact of the COVID-19 pandemic. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three months ended March 31, 2021 and 2022, disaggregated by source and nature, are as follows: For the Three Months Ended March 31, 2021 2022 Net revenues from non-contracted payers $ 6,314 $ 7,262 Net revenues from contracted payers* 11,341 12,645 Net commercial revenues 17,655 19,907 Development services revenues 39 38 Kits and Specimen Collection Tubes (SCTs) 62 — Total net revenues $ 17,756 $ 19,945 *Includes Medicare, Medicare Advantage and CARES Act as reimbursement amounts are fixed. Revenues for the three months ended March 31, 2021 and 2022 included $17.7 million and $19.9 million, respectively, in commercial test revenues, including $16.8 million and $18.6 million of revenues attributable to RT-PCR COVID-19 testing. During the three months ended March 31, 2022, no additional account receivable reserves were required, and the Company had approximately $0.6 million in account receivable recoveries for aged receivable balances reserved in prior periods. For the Three Months Ended March 31, 2021 2022 Net commercial revenues $ 17,655 $ 19,907 Development services revenues 39 38 Kits and Blood Collection Tubes (BCT) 62 — Total net revenues $ 17,756 $ 19,945 At March 31, 2021 and March 31, 2022, unbilled account receivables totaled approximately $4.3 million and $2.7 million, respectively. Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2021, and 2022 were as follows: For the Three Months Ended March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 35% 43% Blue Cross Blue Shield 30% 16% Kaiser Permanente 3% 14% The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2021 and March 31, 2022 were as follows: December 31, March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 31% 36% Blue Cross Blue Shield 19% 16%
Recent Accounting Pronouncements	Recent Accounting Pronouncements None.

The Company, Business Activit_3

The Company, Business Activities and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Composition of Net Revenues Recognized Disaggregated by Source and Nature	The composition of the Company’s net revenues recognized during the three months ended March 31, 2021 and 2022, disaggregated by source and nature, are as follows: For the Three Months Ended March 31, 2021 2022 Net revenues from non-contracted payers $ 6,314 $ 7,262 Net revenues from contracted payers* 11,341 12,645 Net commercial revenues 17,655 19,907 Development services revenues 39 38 Kits and Specimen Collection Tubes (SCTs) 62 — Total net revenues $ 17,756 $ 19,945 *Includes Medicare, Medicare Advantage and CARES Act as reimbursement amounts are fixed. For the Three Months Ended March 31, 2021 2022 Net commercial revenues $ 17,655 $ 19,907 Development services revenues 39 38 Kits and Blood Collection Tubes (BCT) 62 — Total net revenues $ 17,756 $ 19,945
Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage	The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2021, and 2022 were as follows: For the Three Months Ended March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 35% 43% Blue Cross Blue Shield 30% 16% Kaiser Permanente 3% 14% The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2021 and March 31, 2022 were as follows: December 31, March 31, 2021 2022 Medicare and Medicare Advantage/CARES Act 31% 36% Blue Cross Blue Shield 19% 16%

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 3.00 Exercise price $ 3.495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2022
Balance Sheet Component [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, March 31, 2021 2022 (unaudited) Inventories Raw materials $ 2,303 $ 2,735 Subassemblies 294 414 Finished goods 54 72 $ 2,651 $ 3,221 Fixed Assets Machinery and equipment $ 3,063 $ 3,079 Furniture and office equipment 161 161 Computer equipment and software 2,931 2,931 Leasehold improvements 634 634 Construction in process 245 387 $ 7,034 $ 7,192 Less: accumulated depreciation and amortization (4,633 ) (4,812 ) Total fixed assets, net $ 2,401 $ 2,380 Accrued Liabilities Accrued payroll 725 992 Accrued vacation 961 818 Accrued bonuses 178 493 Accrued sales commissions 600 1,813 Accrued other 554 434 Total accrued liabilities $ 3,018 $ 4,550

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Right-Of-Use Lease Assets	The following schedule sets forth the components of right-of-use lease assets as of December 31, 2021 and March 31, 2022 as follows: December 31, March 31, 2021 2022 Lease right-of-use assets: Operating $ 9,026 $ 8,892 Finance 2,842 2,617 Total $ 11,868 $ 11,509
Schedule of Current Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2021 and March 31, 2022: December 31, March 31, 2021 2022 Current portion of lease liability: Operating $ 426 $ 449 Finance 1,083 1,021 Total $ 1,509 $ 1,470
Schedule of Long-Term Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2021 and March 31, 2022: December 31, March 31, 2021 2022 Long-term portion of lease liability: Operating $ 9,736 $ 9,598 Finance 1,428 1,221 Total $ 11,164 $ 10,819
Schedule of Lease Expenses	The following schedule represents the components of lease expense for the three months ended March 31, 2021 and 2022: For the Three Months Ended March 31, 2021 2022 Lease cost Finance lease cost Amortization of right-of-use assets $ 172 $ 225 Interest on lease liabilities 65 61 Operating lease cost 415 415 Total $ 652 $ 701
Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases	The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of March 31, 2022: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2022 (Remaining 9 months) $ 819 $ 92 $ 1,191 2023 $ 963 $ 106 $ 1,629 2024 534 29 1,672 2025 185 3 1,715 2026 15 - 1,762 Thereafter - - 8,518 Total payments 2,516 230 16,487 Less amount representing interest (274 ) — (6,440 ) Present value of payments $ 2,242 $ 230 $ 10,047
Supplemental Cash Flow Information Related to Operating and Finance Leases	The following schedule sets forth supplemental cash flow information related to operating and finance leases as of March 31, 2021 and March 31, 2022: For the Three Months Ended March 31, 2021 2022 Other information Operating cash flows from finance leases $ 65 $ 61 Operating cash flows from operating leases $ 53 $ 396 Financing cash flows from finance leases $ 321 $ 268

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2022 is as follows: Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term in Years Outstanding at December 31, 2021 2,413,194 $ 7.04 9.06 Granted 1,155,570 $ 2.35 Cancelled/forfeited/expired (365,250 ) $ 6.44 Outstanding at March 31, 2022 3,203,514 $ 5.50 7.80 Vested and unvested expected to vest, March 31, 2022 3,162,485 $ 5.52 7.78
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2022 were as follows: 2022 Stock and exercise prices $2.32 - $2.39 Expected dividend yield 0.00% Discount rate-bond equivalent yield 1.76% - 2.41% Expected life (in years) 5.55 - 6.03 Expected volatility 161% - 163%
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the Three Months Ended March 31, 2021 2022 Stock Options Cost of revenues $ 94 $ 208 Research and development expenses 44 166 General and administrative expenses 260 1,802 Sales and marketing expenses 62 141 Total expenses related to stock options 460 2,317

Common Stock Warrants Outstan_2

Common Stock Warrants Outstanding (Tables)	3 Months Ended
	Mar. 31, 2022
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the three months ended March 31, 2022 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2021 857,261 $ 31.73 2.2 Issued — $ — — Exercised — $ — — Expired — $ — — Outstanding at March 31, 2022 857,261 $ 31.73 2.0

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the Three Months Ended March 31, 2021 2022 Common warrants outstanding 991,863 857,261 RSUs outstanding 36 36 Convertible preferred stock outstanding (number of common stock equivalents) 46,651 46,136 Common options outstanding 1,213,284 3,203,514 Total anti-dilutive common share equivalents 2,251,834 4,106,947

The Company, Business Activit_4

The Company, Business Activities and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
The Company Business Activities And Basis Of Presentation [Line Items]
Net revenues	$ 19,945	$ 17,756
Reserves related to aged account receivable		600
Unbilled accounts receivables	2,700	4,300
Commercial Test Revenue [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Net revenues	19,900	17,700
Commercial Test Revenue [Member] | RT-PCR COVID-19 Testing [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Net revenues	$ 18,600	$ 16,800
ASC 606 [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Performance obligation, description of timing	The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks, and for our RT-PCR COVID-19 testing, typically 48 hours or less.
Practical expedient, description	The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
ASC 606 [Member] | Maximum [Member] | Sales and Marketing Expenses [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Amortization period	1 year

The Company, Business Activit_5

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 19,945	$ 17,756
Commercial Revenues [Member] | Commercial Revenues
Disaggregation Of Revenue [Line Items]
Total net revenues		19,907	17,655
Commercial Revenues [Member] | Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues	[1]	12,645	11,341
Commercial Revenues [Member] | Non-Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		7,262	6,314
Development Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 38	39
Kits and Specimen Collection Tubes (SCTs)
Disaggregation Of Revenue [Line Items]
Total net revenues			$ 62
[1]	Includes Medicare, Medicare Advantage and CARES Act as reimbursement amounts are fixed.

The Company, Business Activit_6

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 19,945	$ 17,756
Commercial Revenues [Member] | Commercial Revenues
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	19,907	17,655
Development Services Revenues [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 38	39
Kits and Specimen Collection Tubes (SCTs)
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues		$ 62

The Company, Business Activit_7

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Customer Concentration Risk [Member] | Net Revenues [Member] | Medicare and Medicare Advantage [Member] | Cares Act [Member]
Concentration Risk [Line Items]
Concentration risk percentage	43.00%	35.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	16.00%	30.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | Kaiser Permanente [Member]
Concentration Risk [Line Items]
Concentration risk percentage	14.00%	3.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Medicare and Medicare Advantage [Member] | Cares Act [Member]
Concentration Risk [Line Items]
Concentration risk percentage	36.00%		31.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	16.00%		19.00%

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash And Cash Equivalents [Abstract]
Cash	$ 27,566		$ 28,864
Accumulated deficit	269,119		266,351
Net income (loss)	(2,768)	$ 2,599	(2,800)
Cash flows from operations	(932)	844	$ 800
Aggregate net interest-bearing indebtedness related to financed capital leases	2,200
Aggregate net interest-bearing indebtedness due within one year	1,000
Other non-interest bearing current liabilities	13,100
Net revenues	$ 19,945	$ 17,756

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	May 12, 2021	Jan. 31, 2020	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jan. 31, 2018
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants						$ 18,000
Fair value of warrants issued		$ 1,900,000
Warrant inducement expense			$ 130,000	$ 60,000			$ 2,100,000
Sales Agreement [Member] | Sales Agent [Member]
Class Of Stock [Line Items]
Stock price							$ 4.31
Shares issued in offering							3,428,680
Number of days prior notice to terminate sales agreement	10 days
Percentage of fixed commission to sales agent rate equal to gross sales price per share of common stock sold under sales agreement	3.00%
Net cash proceeds from sale of securities							$ 14,100,000
Common stock remained available for sale					$ 10,200,000
Maximum [Member] | Sales Agreement [Member] | Sales Agent [Member]
Class Of Stock [Line Items]
Shares issued in offering	25,000,000
Warrant [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock								89,657
Stock price		$ 3.495						$ 4.05
Over-allotment Option [Member] | Warrant [Member]
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants		$ 700,000
Shares issued in offering		192,750
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants		$ 2,300,000
Number of warrants issued under warrant repricing and exchange transaction		692,725
Warrant inducement expense		$ 191,000
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member] | Warrant [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock		692,725

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Jan. 10, 2020	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations				$ 0	$ 894,000
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,900,000
Estimated grant date fair value of warrants	$ 2.80
Exercise price of unregistered warrants	3.495
Adjusted exercise price of warrants		$ 12.50	$ 12
Estimated fair value of warrants		2.70	2.70
Estimated fair value of warrants increased		$ 3	$ 2.90
Warrants eligible for price modification		476,000	216,725
Warrant inducement expense		$ 130,000	$ 60,000			$ 2,100,000
Warrant Inducement Transaction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants	$ 3.495
Class of warrant or rights, term	5 years 6 months
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock	692,725
Estimated Fair Value Measurements, Nonrecurring [Member] | Level 3 Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations				$ 0	$ 900,000

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) - September 20, 2018 Offering [Member]	Mar. 31, 2022$ / shares
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 3
Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	3.495
Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	0
Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	1.66
Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	150.33

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventories
Raw materials	$ 2,735	$ 2,303
Subassemblies	414	294
Finished goods	72	54
Inventory, Gross	3,221	2,651
Fixed Assets
Machinery and equipment	3,079	3,063
Furniture and office equipment	161	161
Computer equipment and software	2,931	2,931
Leasehold improvements	634	634
Construction in process	387	245
Total fixed assets, gross	7,192	7,034
Less: accumulated depreciation and amortization	(4,812)	(4,633)
Total fixed assets, net	2,380	2,401
Accrued Liabilities
Accrued payroll	992	725
Accrued vacation	818	961
Accrued bonuses	493	178
Accrued sales commissions	1,813	600
Accrued other	434	554
Total accrued liabilities	$ 4,550	$ 3,018

Leases - Additional Information

Leases - Additional Information (Detail)	Jun. 05, 2020USD ($)	Jun. 01, 2020USD ($)ft²	Mar. 31, 2004USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)mo	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Jan. 01, 2019USD ($)
Leases [Line Items]
Finance lease right-of-use assets				$ 2,617,000		$ 2,842,000
Total amount from equipment financing commitment					$ 894,000
Finance lease transaction, frequency of payments					monthly
Finance lease transaction, monthly installments of principal and interest payments					$ 21,330
Finance lease transaction, total amount to be repaid					$ 1,100,000
Finance lease transaction, commitment period					2026-03
Operating lease monthly payments				396,000	$ 53,000
Operating lease, right-of-use asset				8,892,000		9,026,000
Operating lease liability				$ 10,047,000
Finance lease, weighted average remaining lease term				2 years 6 months
Operating lease, weighted average remaining lease term				9 years 3 months
Finance lease, weighted average discount rate, percent				19.00%
Operating lease, weighted average discount rate, percent				12.00%
Additional exchanges of right of use assets for financed lease liabilities				$ 0
ASC Topic 842 [Member]
Leases [Line Items]
Finance lease right-of-use assets								$ 1,400,000
Financed equipment				6,000,000		6,000,000
Accumulated depreciation related to equipment under finance leases				3,400,000		3,200,000
Depreciation expense related to equipment under finance leases				$ 225,000	$ 172,000
Operating lease transaction, frequency of payments			monthly cash payment
Operating lease monthly payments			$ 120,000
Operating lease term			Jul. 31, 2020
Operating lease, right-of-use asset								1,900,000
Operating lease liability								$ 2,200,000
Operating lease incremental borrowing rate								4.50%
ASC Topic 842 [Member] | 5810 Nancy Ridge Road in San Diego, California [Member]
Leases [Line Items]
Operating lease, right-of-use asset	$ 482,000
Operating lease liability	$ 482,000
Lessee, operating lease, option to extend				Pursuant to the Amendment, the expiration date of the lease was extended from July 31, 2020 to November 30, 2020.
Lease expire date	Nov. 30, 2020
Lessee, operating lease, existence of option to extend	true
Additional extension facility extending the lease	December 11, 2020
ASC Topic 842 [Member] | 9955 Mesa Rim Road in San Diego, California [Member]
Leases [Line Items]
Operating lease monthly payments		$ 128,000
Operating lease, right-of-use asset							$ 9,800,000
Operating lease liability							9,800,000
Operating lease incremental borrowing rate		12.00%
Lease agreement | ft²		39,000
Lease commenced date		Dec. 1, 2020
Lessee, operating lease, term of contract		127 months
Lease term, description				The lease includes a rent abatement period of seven months, from January 2021 through July of 2021, during which period the Company is exempted from paying the amount of base rent of $111,000.
Rent Expense		$ 111,000
Leasehold improvement allowance		1,600,000
Additional leasehold improvement allowance		$ 1,600,000
Additional rent payment of percentage		7.00%
Additional rent payment		$ 18,000
Lessee operating lease initial monthly lease payments		$ 140,000
Reimbursable leasehold improvement costs						$ 1,800,000	$ 1,600,000
Minimum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo					36
Minimum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life				5 years
Maximum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo					60
Maximum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life				7 years

Leases - Schedule of Right-Of-U

Leases - Schedule of Right-Of-Use Lease Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lease right-of-use assets:
Operating	$ 8,892	$ 9,026
Finance	2,617	2,842
Total	$ 11,509	$ 11,868

Leases - Schedule of Current Po

Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current portion of lease liability:
Operating	$ 449	$ 426
Finance	1,021	1,083
Total	$ 1,470	$ 1,509

Leases - Schedule of Long-Term

Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Long-term portion of lease liability:
Non-current portion of lease liabilities - operating	$ 9,598	$ 9,736
Finance	1,221	1,428
Total	$ 10,819	$ 11,164

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Finance lease cost
Amortization of right-of-use assets	$ 225	$ 172
Interest on lease liabilities	61	65
Operating lease cost	415	415
Total	$ 701	$ 652

Leases - Schedule of Remaining

Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail) $ in Thousands	Mar. 31, 2022USD ($)
Financing Lease Minimum Payment Abstract
2022 (Remaining 9 months)	$ 819
2023	963
2024	534
2025	185
2026	15
Total payments	2,516
Less amount representing interest	(274)
Present value of payments	2,242
Financing Lease Maintenance and Sales Tax Obligation Payments Abstract
2022 (Remaining 9 months)	92
2023	106
2024	29
2025	3
Total payments	230
Present value of payments	230
Operating Lease Minimum Payment Abstract
2022 (Remaining 9 months)	1,191
2023	1,629
2024	1,672
2025	1,715
2026	1,762
Thereafter	8,518
Total payments	16,487
Less amount representing interest	(6,440)
Present value of payments	$ 10,047

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other information
Operating cash flows from finance leases	$ 61	$ 65
Operating cash flows from operating leases	396	53
Financing cash flows from finance leases	$ 268	$ 321

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	Mar. 22, 2022	Feb. 14, 2022	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding			3,203,514	2,413,194
Unrecognized share-based compensation expense, weighted-average recognition period			2 years 11 months 19 days
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding			$ 0	$ 610
Intrinsic value of options exercisable			0	610
Intrinsic value of options vested and unvested expected to vest			$ 0	$ 610
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
RSUs granted			0
Intrinsic value shares, RSUs outstanding			$ 84
Intrinsic value amount, RSUs unvested and vested expected to vest			$ 84
RSUs outstanding			36
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense, stock options			$ 6,500,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			2,263,088
2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance			1,300,000
Total stock options and RSUs authorized			2,336,409
Stock options and RSUs issued			1,858,427
Common stock, shares authorized			667,663
Total Shares Outstanding			1,603,596
2013 Equity Incentive Plan [Member] | Inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance	500,000	1,000,000
Total stock options and RSUs authorized			2,263,088
Stock options and RSUs issued			1,599,918
Common stock, shares authorized			513,032
Total Shares Outstanding			1,599,918
2013 Equity Incentive Plan [Member] | Non-inducement and Inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			4,599,497

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	2,413,194
Number of Shares, Granted	1,155,570
Number of Shares, Cancelled/forfeited/expired	(365,250)
Number of Shares Outstanding, Ending Balance	3,203,514	2,413,194
Number of Shares, Vested and unvested expected to vest, Ending Balance	3,162,485
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 7.04
Weighted Average Exercise Price Per Share, Granted	2.35
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	6.44
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	5.50	$ 7.04
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 5.52
Weighted Average Remaining Contractual Term in Years, Outstanding	7 years 9 months 18 days	9 years 21 days
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest	7 years 9 months 10 days

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2022$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 2.32
Discount rate-bond equivalent yield	1.76%
Expected life (in years)	5 years 6 months 18 days
Expected volatility	161.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 2.39
Discount rate-bond equivalent yield	2.41%
Expected life (in years)	6 years 10 days
Expected volatility	163.00%

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - Stock Options [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 2,317	$ 460
Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	208	94
Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	166	44
General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,802	260
Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 141	$ 62

Common Stock Warrants Outstan_3

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	857,261
Number of Shares, Outstanding, Ending Balance	857,261	857,261
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 31.73
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 31.73	$ 31.73
Average Remaining Contractual Term (in years)	2 years	2 years 2 months 12 days

Common Stock Warrants Outstan_4

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)	1 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	May 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Common stock warrants outstanding, intrinsic value						$ 0	$ 16,000
Warrant [Member] | February 2019 Financing Transaction [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date					Feb. 12, 2024
Warrant [Member] | March 2019 Transaction [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date				Sep. 19, 2024
Warrant [Member] | May 2019 Inducement Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date			Dec. 2, 2024
Warrant [Member] | December 2019 Underwritten Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date		Dec. 11, 2024
Warrant [Member] | January 2020 Inducement Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date	Jul. 10, 2025

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021shares
Earnings Per Share [Abstract]
Number of warrants included in the calculation of dilutive weighted average shares	256,461
Number of options included in the calculation of dilutive weighted average shares	102,708
Additional shares included in the calculation of diluted net income per share	267,709

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	4,106,947	2,251,834
Convertible Preferred Stock Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	46,136	46,651
Common Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	857,261	991,863
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	36	36
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	3,203,514	1,213,284

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Mar. 31, 2022USD ($)
Loss Contingencies [Line Items]
Commission accrual for probable loss	$ 1.6
Minimum [Member]
Loss Contingencies [Line Items]
Sales commission dispute, probable loss	1.5
Maximum [Member]
Loss Contingencies [Line Items]
Sales commission dispute, probable loss	$ 1.8

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Aegea Biotechnologies, Inc [Member] - USD ($)	Jan. 01, 2019	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022
Related Party Transaction [Line Items]
Reimbursement for shared patent costs		$ 49,000	$ 36,000
Percentage of royalty on sale of product	10.00%
Accrued royalty expense		$ 0		$ 0